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ABSTRACT
Alzheimer’s disease (AD) is a devastating
neurodegenerative disorder affecting the
elderly. Current clinical diagnostic tools are
often ineffective in accurately diagnosing AD.
However, new advances in diagnostic imaging,
particularly positron emission tomography
(PET) amyloid imaging, have shown increased
sensitivity and specificity, as well as high inter-
reader agreement. The most commonly studied
tracer, PiB-C11, has shown high affinity binding
to amyloid, but is limited in its use outside of
research due to its short half-life. Instead,
development of other PET ligands with
increased half-life, such as fluorine-18-labeled
(18F) tracers, allows for more widespread use of
PET in clinical settings. In particular, recent
phase II and III trials of 18F-florbetaben have
demonstrated the high accuracy of this PET
tracer in identifying amyloid accumulation.
This paper will examine the techniques of
amyloid imaging, focusing particularly on the
recently approved 18F-florbetaben.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive
neurodegenerative disorder and the most
common form of dementia in the elderly [1].
According to the US Centers for Disease Control
and Prevention (CDC), AD is the fifth leading
cause of death for persons aged 65 years and
older [2].
Alzheimer’s disease may occur sporadically
or as a result of rare genetic mutations that
produce an autosomal dominant form of the
disease. Clinical features of AD include amnesic
memory impairment, language deterioration
and visuospatial deficits, as well as functional
and behavioral disturbances [1]. Treatment of
AD includes cholinesterase inhibitors such as
donepezil, galantamine, and rivastigmine, with
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mixed evidence of efficacy that vary depending
on symptom. For example, one meta-analysis
found all three drugs to have similar efficacy in
treating cognition, but favored donepezil over
galantamine when treating behavior [3].
Early diagnosis is important, with one study
reporting that identifying and treating AD
patients at an early stage could result in cost
savings and health benefits, such a reduction in
money spent in services and care for patients
and families [4]. The establishment of probable
AD or other types of dementia often relies on
clinical criteria set forth in the 1980s by the
National Institute of Neurological and
Communicative Disorders and Stroke
(NINCDS) and the Alzheimer’s Disease and
Related Disorders Association (ADRDA).
Differentiation between AD, other dementias
and normal decline is based on medical history,
clinical examinations and laboratory studies, as
well as genetic, neuropsychological and
pathophysiological testing [5]. However,
clinical diagnosis remains imperfect, with one
meta-study finding high variability of
sensitivity and specificity for clinical diagnoses
criteria, ranging from 53.0 to 100.0% and 55.0
to 99.0%, respectively. For those studies that
included neuropathological verification as the
gold standard of diagnosis, clinical criteria
NINCDS–ADRDA produced a sensitivity of
76–93% and a specificity of 55–91% [6].
BIOMARKERS AND DIAGNOSTIC
METHODS
Although the underlying etiology of AD is not
fully understood, several potential biomarkers
have been identified in the disease progression,
such as beta-amyloid and tau proteins. Such
biomarkers can be measured either in
cerebrospinal fluid (CSF) and, more recently,
directly in brain tissue using specialized
imaging. Beta-amyloid peptide is currently
believed to be an important component of the
disease process and the amyloid plaques that
result from the accumulation of the protein are
considered to be one of the hallmarks of AD.
Furthermore, these plaques have become a vital
part of neuropathological diagnostic criteria,
with current imaging techniques using
radiolabeled tracers that bind to the amyloid
peptides of amyloid plaques, potentially
allowing physicians to directly measure plaque
pathology through the use of diagnostic
imaging [7]. In fact, the International Working
Group (IWG-2) stressed the utility of biomarkers
for diagnosis of AD in cases where diagnosis
may not have previously been possible.
Specifically, they state that tools like magnetic
resonance imaging (MRI), positron emission
tomography (PET), and CSF analyses have
allowed for diagnosis in the ‘‘prodromal stage’’,
before dementia has even appeared [8].
As stated, one method in diagnosing AD is the
measurement of biomarkers in CSF. Specifically,
AD is associated with an increase in total tau
(T-tau) and phosphorylated tau (P-tau), and a
decrease in amyloid b-protein 1–42 (Ab1–42). A
study comparing the diagnostic accuracy of MRI,
single-photon emission computed tomography
(SPECT), fluorodeoxyglucose-positron emission
tomography (FDG-PET), and CSF, found higher
percentages of positive results using CSF
biomarkers (94%), compared with MRI (77.4%)
and cerebral blood flow-single-photon emission
computed tomography (CBF-SPECT) (81.6%). At
Clinical Dementia Rating (CDR) 0.5, 90.0% of
patients had positive results using CSF
biomarkers; specifically 87.5% with P-tau and
86.7% with T-Tau. Overall, the positive
percentage for CSF biomarkers was 95.2% [9].
Another study found CSF biomarkers produced a
sensitivity of 89.4% and specificity of 70.5% [10].
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In regards to specific biomarkers, a meta-
analysis found that T-tau and P-tau produced a
sensitivity of 73.3–86.0% and specificity from
70.0 to 92.4%. Combined CSF T-tau and P-tau
produced a sensitivity of 81.0% and specificity
of 91.0%. CSF Ab1–42 showed a pooled
sensitivity of 85.0 to -100.0% and a specificity
of 63.0–90.8%. Finally, combined T-tau, P-tau,
and Ab produced a sensitivity of 85.0–90.0%,
with no specificity reported [6].
FUNCTIONAL IMAGING
Functional imaging can capture both static and
dynamic brain activities in living patients,
allowing for measurements of brain
physiological processes such as oxygen use,
blood perfusion, and glucose metabolism. The
most frequently used imaging techniques in
identifying and tracking dementia include MRI,
SPECT and PET. PET in particular uses positron
emitters to label specific brain processes. These
positrons are unstable and interact with
electrons within brain tissue, producing
photons and thus measurable signals [11].
Fluorine-18 (18F)-labeled compounds in
general have been shown to be an important
group of radiotracers. As AD is associated with
reduced glucose metabolism due to reduced
cellular activity, 18F fluorodeoxyglucose (FDG)
allows for the measurement of changes in
glucose metabolism in the brain. This tracer
is intravenously injected, phosphorylated in
glucose-consuming cells, and then retained in
these cells. FDG uptake in a resting state is
primarily driven by basal neuronal activity,
reflective of neuronal integrity. Thus, AD
patients show reduced FDG-PET signal in
regions associated with degeneration:
specifically in the temporal–parietal, posterior
cingulate and frontal cortex—regions
associated with memory and orientation [11].
Its long half-life also allows for longer intervals
between production and injection.
Furthermore, the labeled specific activities of
18F tracers can be increased to levels higher
than those of 11C tracers, meaning significantly
lower amounts of unlabeled ligand are needed
to be injected [7].
AMYLOID IMAGING
Developments in molecular imaging using PET
have also allowed for visualization of fibrillar
beta-amyloid plaques in the brains of living AD
patients. However, although amyloid PET
imaging has allowed for a better
understanding of the accumulation of beta-
amyloid in vivo, the tracers’ molecular
mechanisms and binding properties in both
AD and healthy brains is not yet fully
understood [12, 13].
The first amyloid-imaging agent to be
successfully used in humans was 18fluoro-
labeled 1,1-dicyano-2-[6-(dimethylamino)-2-
naphthalenyl]propene (FDDNP). This
compound was the fluorinated derivative of a
cell membrane dye and was able to bind in vitro
to beta-amyloid, tau and prion proteins [7].
Current amyloid tracers belong to a variety
of chemical classes such as thioflavin T
(including 11C-PIB, 18F-flutemetamol, and
11C-AZD2184), stilbenes (18F-AV-1, 18F-AV-45,
and 11C-SB-13), benzoxazoles (11C-BF-227 and
18F-BF-227), and benzofurans (18F-AZD4694).
Researchers theorize that the different
chemical classes suggest that these tracers
differ in how they bind to fibrillar
beta-amyloid, as well as other forms of
beta-amyloid [12, 13].
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PiB-C11
Currently, the most widely studied tracer is
PiB-C11, the first agent to show clear retention
in known regions associated with AD amyloid
pathology. PiB-C11 binds to both extracellular
and intravascular fibrillar amyloid deposits, but
not to neurofibrillary tangles (NFTs) or Lewy
Bodies. FDDNP, however, does bind to NFTs,
thus serving as a potential complement to
PiB-C11 amyloid scans. The tracer also binds
non-specifically to white matter [7]. However,
while cortical retention of the tracer is higher in
AD, PiB-C11 shows high variability of binding
and no correlation with disease severity [14]. In
terms of uptake characteristics, one study
reported a PET time of 20, 50-min post-
intravenous injection [15].
In the first human study of PiB-C11,
researchers found that AD patients showed
significantly increased retention in areas of the
cortex known to accumulate high levels of
amyloid in AD. Specifically, PiB-C11 retention
was increased most prominently in frontal
cortex, as well as the striatum and parietal,
temporal, and occipital cortex. Furthermore,
retention was not significantly increased in
regions known to develop little amyloid
accumulation in the disease process [16].
The primary drawback of PiB-C11 is its
20-min half-life, limiting its broader clinical
application [15, 17]. However, 18F-labeled PET
tracers have the potential for more clinical use
due to their longer half-life of 110 min [15].
18F Tracers
In terms of imaging characteristics, a negative
18F-amyloid scan shows distinctive binding in
white matter, while positive scans show
binding in cortical gray matter that obscures
the typical white matter pattern; in fact,
white matter uptake is greater for 18F tracers
than for Pib-C11. More specifically, a negative
scan will display a clear image of the corpus
callosum and pons in a midline sagittal slice,
and transverse slices will display normal
white matter patterns. A separation of
hemispheric activity will also be seen,
particularly in the medial orbitofrontal and
precuneus areas [14].
Currently, three 18F-labeled amyloid tracers
have been evaluated in clinical studies and
approved for use by the FDA: 18F-AV-45
(18F-florbetapir; AMYViDTM), 18F-flutemetamol





vinyl)-N-methylbenzenamine) has been shown
to have high affinity, specific binding to
amyloid plaques of 3.1 nM [18]. In regards to
uptake characteristics, PET scan time has been
reported as 10, 50 min after intravenous
injection of F18-florbetapir [19].
An early phase human study of
18F-florbetapir found an accumulation of the
tracer in cortical regions such as the frontal
cortex, temporal cortex, and precuneus, which
were expected to be high in beta-amyloid
deposition. In contrast, the controls showed
tracer accumulation in predominantly white
matter area [20].
Another study found cortical retention of
18F-florbetapir was highest in subjects with AD,
intermediate in subjects with mild cognitive
impairment (MCI), and lowest in cognitively
normal subjects, regardless of whether the
assessment was via the standardized uptake
value ratio (SUVR), visual ratings or binary
classification [21].
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In one study comparing 18F-florbetapir PET
with postmortem histopathology, researchers
found high correlations between the autopsy
and imaging findings from AD subjects.
Specifically, of the fifteen participants that met
the pathological criteria for AD at autopsy,
fourteen had positive 18F-florbetapir scans. Of
the fourteen participants found pathologically
negative for AD at autopsy, all fourteen were
read as negative on 18F-florbetapir PET [22].
Another study examining correlations with
other diagnostic techniques found
18F-florbetapir, similar to PiB-C11, showed
high in vivo agreement with postmortem
histopathology with sensitivities and
specificities exceeding 95%. When comparing
18F-florbetapir to PiB-C11, researchers found
similar binding characteristics, with both
ligands able to discriminate healthy controls
from mild AD, although there was less overlap
with PiB-C11. Researchers theorized this may
have been due to greater relative non-specific
white matter uptake of 18F-florbetapir compared
to cortical uptake. In addition, while all brain
regions displayed high correlation between the
ligands, the SUVR ranges between the lowest
and highest values was larger for the PiB-C11
PET scans [15].
Flutemetamol
18F-flutemetamol is a PiB analog developed by
GE Healthcare and was developed as an F18
amyloid-imaging agent that would not have the
limitations of C11 agents. Sensitivity and
specificity were found to be 93.1% and 93.3%,
respectively [7]. In terms of imaging
characteristics, 18F-flutemetamol shows high
intensities in the pons and cerebellar white
matter. Furthermore, the center of high-
intensity regions show another region of low
intensity associated with the fourth ventricle
[23]. One study found cerebral cortical uptake
of 18F-flutemetamol to be strongly correlated
with tissue biopsy beta-amyloid levels.
Researchers also found 18F-flutemetamol
uptake ratios in PET images to be highly
specific for abnormal amyloid deposits in the
brain, with moderate to high sensitivity. Single
doses were well tolerated. In terms of uptake
characteristics, PET imaging was performed
90-min post-injection and completed within
20 min [24].
Florbetaben
18F-florbetaben was the first 18F-labeled
Ab-tracer studied in humans (FBB; trans-4-
(N-methyl-amino)-400(2-(2-(2-[18F] fluoro-
ethoxy)ethoxy)-ethoxy)stilbene). In a process
described by Zhang et al. [25, 26],
radiosynthesis of 18F-florbetaben involved the
radiolabeling of a non-radioactive precursor
(BOC-Stilbenmesylate) with 18F, followed
by acid hydrolysis and semi-preparative
high-performance liquid chromatography
(HPLC) for purification. Similar to florbetapir,
18F was linked to stilbene through a
polyethylene glycol (PEG), as PEG not only
lowered the lipophilicity, but also improved
overall bioavailability.
The compound has shown specific binding
to beta-amyloid plaques in vivo, with a half
maximal inhibitory concentration (IC50) of
146 nM for inhibition of [125I]IMPY binding
[25, 27]. Another study found the tracer had
high affinity binding (Ki) to beta-amyloid, with
a Ki of 6.7 nM, and did not show binding to
tangles, Pick Bodies, Lewy Bodies, or glial
cytoplasmic inclusions [17]. Early animal
studies found that initial brain uptake of
18F-florbetaben was high at 4.77% injected
dose (ID)/g 2-min post-injection, and blood
serum clearance was rapid at 3.1 l/h/kg.
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Furthermore, bone uptake was low at 4.64% ID/
g at 4-h post-injection. Toxicity trials have
found 18F-florbetaben to be well tolerated with
no mutagenic properties discovered [25]. In
terms of uptake characteristics, PET imaging
was completed in 20 min, following a 90- and
110-min post-injection period [28, 29].
Proof of this mechanism was first
demonstrated in 2008 through PET imaging
of 15 AD patients, five patients with
frontotemporal lobar degeneration (FTLD) and
15 healthy controls. Cortical binding produced
a robust separation of AD patients from both
patients with FTLD and controls, using visual
image interpretation or a simple semi-
quantitative measure from a 20-min PET scan.
Furthermore, researchers found widespread
neocortical binding, particularly in the
posterior cingulate and frontal cortex, with
relative sparing of sensorimotor, occipital and
medial temporal cortex.
A phase 0 study of 18F-florbetaben PET found
that 9 in 10 AD patients were amyloid positive,
with high inter-reader agreement. Neocortical
SUVRs were significantly higher in the AD
patients’ frontal cortex, lateral temporal
cortex, occipital cortex and anterior and
posterior cingulate cortices as well as the
parietal cortex [30].
A phase II diagnostic study was designed to
assess and refine PET scan acquisition and
assessment techniques, compare different
imaging time points, develop a visual
assessment algorithm and develop a
quantitative assessment tool. Diagnostic
efficacy did not differ significantly across the
tested imaging periods, suggesting an added
benefit of flexibility in the clinical setting [31].
The clinical phase II study confirmed the initial
efficacy findings of the phase 1 studies in a
larger study population, including individuals
of varying age and different race. Based on these
results, a visual assessment methodology and
reader training was developed to be applied in
future clinical practice. This methodology has
been used successfully in the pivotal efficacy
studies.
Another study comparing 18F-florbetaben to
PiB-C11 found a high correlation between the
two tracers in terms of high retention in the
cortical and subcortical gray matter and lower
coefficients in white matter. Researchers also
found that both radiotracers were able to
robustly distinguish AD from healthy controls,
even with a short PET scan, which would be
more easily tolerated by elderly patients.
Researchers also noted that while there were
no differences in white matter retention for
both healthy controls and AD participants
using either tracer, the frontal cortex to white
matter ratios for PiB-C11 were higher in healthy
controls (0.77) and AD (1.45) participants
compared to the ratios for 18F-florbetaben in
healthy controls and AD (0.70 and 1.12,
respectively) [32].
Another study found 18F-florbetaben to be
useful in distinguishing AD from healthy
controls, as well as other neurodegenerative
disorders. Specifically, 96% of patient with AD
and 60% of patients with MCI displayed broadly
distributed cortical 18F-florbetaben retention,
compared to 9% of patients with FTLD, 25%
of patients with vascular dementia (VaD), 29%
of patients with dementia with Lewy bodies
(DLB), and 16% of healthy controls. Sensitivity
and specificity was found to be 97% and 88%,
respectively [29].
One study found 18F-florbetaben to be
effective in assessing brain beta-amyloid levels
in individuals with MCI. 45 patients with MCI
underwent FBB positron emission tomography.
At baseline, 24 (53%) patients with MCI were
FBB?. In 2 years, 18 (75%) FBB? patients
progressed to AD compared with 2 (9.5%) FBB-
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patients, yielding a predictive accuracy of 83%
[95% confidence interval (CI) 61–94%] [32]. The
florbetaben phase III trial was an open-label,
non-randomized study designed to evaluate the
efficacy and safety of florbetaben PET imaging
for the detection/exclusion of cerebral beta-
amyloid. Subjects with a low probability of
cerebral beta-amyloid deposition [e.g., non-
demented volunteers (NDVs)] and subjects
with a high probability of beta-amyloid
deposition (e.g., subjects diagnosed with AD or
DLB) were included in the trial. Determination
of the presence or absence of florbetaben uptake
in the PET scan was compared to postmortem
histopathology as the standard of truth. Ten
young healthy volunteers were included as
additional negative controls. The design of the
florbetaben phase III study served two different
goals: the regional tissue-matched analysis with
MRI co-registration was designed as a ‘‘target
validation’’ study, aiming to provide pivotal
support for the validity of florbetaben PET
imaging to detect amyloid aggregates in
precisely the same tissue as that examined by
histopathology. The subject-level analysis of the
florbetaben PET images without MRI co-
registration was designed to provide pivotal
support for the visual assessment methodology
intended for clinical use. In areas known to
show beta-amyloid plaques more frequently in
AD (i.e., frontal cortex, anterior cingulate and
posterior cingulate/precuneus area), the
regional tissue-matched analysis showed a
sensitivity of 82–90% and specificity of
86–95%. Sensitivity was lower (57%) but
specificity higher (100%) for the hippocampus,
resulting in an overall sensitivity of 77.4% (95%
CI 65.3–89.4%) and a specificity of 94.2% (95%
CI 88.6–99.8%) for all regions of interest. In
the regional tissue-matched quantitative
florbetaben PET assessment, significantly
higher SUVRs were found for regions
confirmed to have histopathological evidence
of beta-amyloid compared with regions that
were scored negatively for beta-amyloid, with
the exception of the hippocampus/
parahippocampal gyrus, consistent with the
visual assessment suggesting that the unique
anatomy of this region limits the reliability of
PET assessment. Furthermore, PET scan reads on
a subject-level (whole brain) were investigated
to determine the sensitivity and specificity of
florbetaben in this setting. The results from the
visual assessment using the method applicable
for clinical routine were compared with the
neuropathological assessment of absence/
presence of beta-amyloid plaques according to
Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) criteria. A
sensitivity of 100% (95% CI 80.5–100.0%), a
specificity of 91.67% (95% CI 80.6–100.0%),
and an almost perfect across-reader agreement
[estimate interrater reliability (j) = 0.870] was
obtained for the first 31 deceased subjects and
the image analyses from 10 young healthy
volunteers who were considered to be negative
for beta-amyloid. (The results from the interim
report were subsequently confirmed in a larger
cohort of subjects and were applied for
approvals in the EU and US. Moreover, the
addition of young, healthy volunteers was no
longer needed as a sufficiently high number of
amyloid-negative subjects became available for
the analyses).
CONCLUSIONS
Recent guidelines have supported the use of
amyloid imaging in a specific set of clinical
situations, including patients with persistent or
progressive MCI, patients who meet the criteria
for possible AD, and patients with progressive
dementia and atypical early onset dementia.
However, some authors have stated that
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amyloid imaging is inappropriate in cases
including: patients with probable AD with
typical age of onset; patients with a positive
family history or apolipoprotein 4 (APOE4)
mutation; patients with unconfirmed cognitive
complaints, in lieu of genotyping, or as a means
of determining severity. They also could not
support the utility of amyloid imaging for non-
medical purposes such as assessing competency
in a legal context or assessing ability to perform
activities for daily living. These guidelines
noted the clinical limitations of C11 due to its
short half-life, stating that 18F-labeled PET half-
life allows for better incorporation into routine
practice. Furthermore, authors have argued that
while the clinical utility based on change in
case management or change in diagnosis has
not yet been established, amyloid PET imaging
may be useful in excluding AD in cases of MCI
complicated with vascular, traumatic or medical
causes [18].
18F-florbetaben is a promising approved PET
radiotracer allowing for more widespread use of
amyloid imaging in clinical settings. The tracer
has the potential for early, reliable detection of
AD disease and can aid in facilitating specific
treatment decisions, due to its improved high
sensitivity and specificity over previous clinical
criteria.
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